CCTN - PHARMACOKINETIC / PHARMACODYNAMIC EVALUATION OF LEVONORGESTREL BUTANOATE FOR FEMALE CONTRACEPTION
CCTN - 丁酸左炔诺孕酮用于女性避孕的药代动力学/药效学评价
基本信息
- 批准号:10497855
- 负责人:
- 金额:$ 11.12万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-09-28 至 2023-09-27
- 项目状态:已结题
- 来源:
- 关键词:AdherenceAgeBody mass indexClinicalClinical Practice GuidelineClinical TrialsClinical Trials NetworkContraceptive AgentsContraceptive methodsContractorDataDevelopmentDoseDrug KineticsEnrollmentEstrogensEvaluationFemale Contraceptive AgentsFree WillGoalsGood Clinical PracticeGovernmentImplantInjectableInjectionsInternationalIntramuscularIntrauterine DevicesLactationLevonorgestrelMissionMonitorNational Institute of Child Health and Human DevelopmentNon obeseObesityPharmacodynamicsPopulationProgestinsProtocols documentationPublic HealthRecording of previous eventsRecordsRegimenRegulationRiskRouteSafetyTimeUnited States Food and Drug AdministrationWomancontraceptive efficacyfollow-uppillprotocol developmentrecruitreproductivesubcutaneoussymposiumvenous thromboembolism
项目摘要
There is a demand for estrogen-free contraception in order to reduce the risk of venous
thromboembolism (VTE), particularly for obese women. A new long-acting ormulation of
levonorgestrel butanoate (LB) delivered by injection has been developed. Levonorgestrel (LNG)
has a long history of clinical use in a variety of contraceptives (pills, intrauterine devices, and
implants) and its efficacy and safety are well recognized.
The Eunice Kennedy Shriver National Institute of Child Health and Human Development
(NICHD) has a mission to develop safe and effective contraceptives for women, including obese
women. Obesity is the number one public health issue facing the US population and is an
independent risk for venous thromboembolism (VTE). Therefore, there is a public health need to
develop effective contraception for obese woman that does not increase the risk of VTE. One
Food and Drug Administration (FDA) -approved contraceptive method is the progestin-only pill
(POP) or so-called "mini pill," which is used mainly by lactating women only for several months
and requires strict adherence to taking the POP at the same time every day. A long-acting
injectable form of LB that is estrogen-free will provide a regimen that is easier to follow than a
POP and have a theoretically lower risk of VTE especially for obese women. In order to provide
preliminary evidence that LB could be effective for contraception, a clinical trial will be
conducted in the NICHD Contraceptive Clinical Trials Network (CCTN).
The proposed study will be conducted in women of reproductive age in order to evaluate
pharmacokinetics, the mechanisms of contraceptive efficacy, and safety of this new
contraceptive. The enrolled subjects will receive LB via intramuscular and subcutaneous routes of
injection. The Recruitment will include enrollment of approximately 50% of subjects with BMI
>=32 kg/m2 but less than 40 kg/m2
为了减少静脉血栓的风险,需要无雌激素避孕。
血栓栓塞(VTE),特别是肥胖女性。一种新的长效制剂
已开发了通过注射递送的丁酸左炔诺孕酮(LB)。左炔诺孕酮(LNG)
在各种避孕药(避孕药、宫内节育器和
植入物)及其有效性和安全性是公认的。
尤妮斯·肯尼迪·施莱佛国家儿童健康和人类发展研究所
(NICHD)的使命是为妇女,包括肥胖妇女,开发安全有效的避孕药具。
妇女肥胖是美国人口面临的头号公共健康问题,
静脉血栓栓塞(VTE)的独立风险。因此,公共卫生需要
为肥胖妇女开发有效的避孕方法,不会增加静脉血栓栓塞的风险。一
美国食品和药物管理局(FDA)批准的避孕方法是孕激素药丸
(POP)也就是所谓的“迷你药丸”,主要由哺乳期妇女使用,
并要求严格坚持每天在同一时间服用POP。长效
不含雌激素LB的可注射形式将提供一种比常规LB更容易遵循的方案,
从理论上讲,特别是对于肥胖女性来说,静脉血栓栓塞的风险较低。以此为您提供
有初步证据表明LB可以有效避孕,一项临床试验将在
NICHD避孕临床试验网络(CCTN)。
拟在育龄妇女中进行研究,以评价
药物动力学,避孕效果的机制,和安全性,这种新的
避孕药入组的受试者将通过肌内和皮下途径接受LB,
注射招募将包括入组约50%的BMI受试者
>=32 kg/m2但小于40 kg/m2
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
CAROLYN L WESTHOFF其他文献
CAROLYN L WESTHOFF的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('CAROLYN L WESTHOFF', 18)}}的其他基金
CCTN - PHARMACOKINETIC / PHARMACODYNAMIC EVALUATION OF LEVONORGESTREL BUTANOATE FOR FEMALE CONTRACEPTION
CCTN - 丁酸左炔诺孕酮用于女性避孕的药代动力学/药效学评价
- 批准号:
10939295 - 财政年份:2018
- 资助金额:
$ 11.12万 - 项目类别:
CCTN - CONTRACEPTIVE CLINICAL TRIALS NETWORK - CORE - FEMALE
CCTN - 避孕临床试验网络 - 核心 - 女性
- 批准号:
9525758 - 财政年份:2017
- 资助金额:
$ 11.12万 - 项目类别:
A Prospective, Randomized Study to Compare Effects of Ulipristal Acetate with a Combined Oral Contraceptive on Breast Epithelial Cell Proliferation.
一项前瞻性随机研究,比较醋酸乌利司他与复方口服避孕药对乳腺上皮细胞增殖的影响。
- 批准号:
9006850 - 财政年份:2016
- 资助金额:
$ 11.12万 - 项目类别:
A Prospective, Randomized Study to Compare Effects of Ulipristal Acetate with a Combined Oral Contraceptive on Breast Epithelial Cell Proliferation.
一项前瞻性随机研究,比较醋酸乌利司他与复方口服避孕药对乳腺上皮细胞增殖的影响。
- 批准号:
9307756 - 财政年份:2016
- 资助金额:
$ 11.12万 - 项目类别:
CCTN - CONTRACEPTIVE CLINICAL TRIALS NETWORK - EVALUATION REVERSIBLE CONTRACEPTIVE
CCTN - 避孕临床试验网络 - 评估可逆避孕药
- 批准号:
9923499 - 财政年份:2015
- 资助金额:
$ 11.12万 - 项目类别:
CCTN - CONTRACEPTIVE CLINICAL TRIALS NETWORK - EVALUATION REVERSIBLE CONTRACEPTIVE
CCTN - 避孕临床试验网络 - 评估可逆避孕药
- 批准号:
9149743 - 财政年份:2015
- 资助金额:
$ 11.12万 - 项目类别:
CCTN - CLINICAL EVALUATION OF NOVEL PRODUCTS FOR FEMALE CONTRACEPTION: PILOT AND EFFICACY STUDY
CCTN - 女性避孕新产品的临床评价:试点和功效研究
- 批准号:
8933135 - 财政年份:2014
- 资助金额:
$ 11.12万 - 项目类别:
CCTN - CLINICAL EVALUATION OF NOVEL PRODUCTS FOR FEMALE CONTRACEPTION: PILOT AND EFFICACY STUDY
CCTN - 女性避孕新产品的临床评价:试点和功效研究
- 批准号:
10271385 - 财政年份:2014
- 资助金额:
$ 11.12万 - 项目类别:
CCTN - CLINICAL EVALUATION OF NOVEL PRODUCTS FOR FEMALE CONTRACEPTION: PILOT AND EFFICACY STUDY
CCTN - 女性避孕新产品的临床评价:试点和功效研究
- 批准号:
10421163 - 财政年份:2014
- 资助金额:
$ 11.12万 - 项目类别:
CCTN - CONTRACEPTIVE CLINICAL TRIALS NETWORK - CORE - FEMALE
CCTN - 避孕临床试验网络 - 核心 - 女性
- 批准号:
8887060 - 财政年份:2013
- 资助金额:
$ 11.12万 - 项目类别:
相似国自然基金
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
- 批准号:JCZRQN202500010
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
- 批准号:2025JJ70209
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
- 批准号:
- 批准年份:2024
- 资助金额:0 万元
- 项目类别:面上项目
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
- 批准号:2023JJ50274
- 批准年份:2023
- 资助金额:0.0 万元
- 项目类别:省市级项目
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
- 批准号:
- 批准年份:2022
- 资助金额:33 万元
- 项目类别:地区科学基金项目
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
- 批准号:
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
- 批准号:n/a
- 批准年份:2022
- 资助金额:10.0 万元
- 项目类别:省市级项目
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
- 批准号:81973577
- 批准年份:2019
- 资助金额:55.0 万元
- 项目类别:面上项目
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
- 批准号:81602908
- 批准年份:2016
- 资助金额:18.0 万元
- 项目类别:青年科学基金项目
高血糖激活滑膜AGE-RAGE-PKC轴致骨关节炎易感的机制研究
- 批准号:81501928
- 批准年份:2015
- 资助金额:18.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Collaborative Research: Resolving the LGM ventilation age conundrum: New radiocarbon records from high sedimentation rate sites in the deep western Pacific
合作研究:解决LGM通风年龄难题:西太平洋深部高沉降率地点的新放射性碳记录
- 批准号:
2341426 - 财政年份:2024
- 资助金额:
$ 11.12万 - 项目类别:
Continuing Grant
Collaborative Research: Resolving the LGM ventilation age conundrum: New radiocarbon records from high sedimentation rate sites in the deep western Pacific
合作研究:解决LGM通风年龄难题:西太平洋深部高沉降率地点的新放射性碳记录
- 批准号:
2341424 - 财政年份:2024
- 资助金额:
$ 11.12万 - 项目类别:
Continuing Grant
PROTEMO: Emotional Dynamics Of Protective Policies In An Age Of Insecurity
PROTEMO:不安全时代保护政策的情绪动态
- 批准号:
10108433 - 财政年份:2024
- 资助金额:
$ 11.12万 - 项目类别:
EU-Funded
The role of dietary and blood proteins in the prevention and development of major age-related diseases
膳食和血液蛋白在预防和发展主要与年龄相关的疾病中的作用
- 批准号:
MR/X032809/1 - 财政年份:2024
- 资助金额:
$ 11.12万 - 项目类别:
Fellowship
Atomic Anxiety in the New Nuclear Age: How Can Arms Control and Disarmament Reduce the Risk of Nuclear War?
新核时代的原子焦虑:军控与裁军如何降低核战争风险?
- 批准号:
MR/X034690/1 - 财政年份:2024
- 资助金额:
$ 11.12万 - 项目类别:
Fellowship
Walkability and health-related quality of life in Age-Friendly Cities (AFCs) across Japan and the Asia-Pacific
日本和亚太地区老年友好城市 (AFC) 的步行适宜性和与健康相关的生活质量
- 批准号:
24K13490 - 财政年份:2024
- 资助金额:
$ 11.12万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Discovering the (R)Evolution of EurAsian Steppe Metallurgy: Social and environmental impact of the Bronze Age steppes metal-driven economy
发现欧亚草原冶金的(R)演变:青铜时代草原金属驱动型经济的社会和环境影响
- 批准号:
EP/Z00022X/1 - 财政年份:2024
- 资助金额:
$ 11.12万 - 项目类别:
Research Grant
ICF: Neutrophils and cellular senescence: A vicious circle promoting age-related disease.
ICF:中性粒细胞和细胞衰老:促进与年龄相关疾病的恶性循环。
- 批准号:
MR/Y003365/1 - 财政年份:2024
- 资助金额:
$ 11.12万 - 项目类别:
Research Grant
Doctoral Dissertation Research: Effects of age of acquisition in emerging sign languages
博士论文研究:新兴手语习得年龄的影响
- 批准号:
2335955 - 财政年份:2024
- 资助金额:
$ 11.12万 - 项目类别:
Standard Grant
Shaping Competition in the Digital Age (SCiDA) - Principles, tools and institutions of digital regulation in the UK, Germany and the EU
塑造数字时代的竞争 (SCiDA) - 英国、德国和欧盟的数字监管原则、工具和机构
- 批准号:
AH/Y007549/1 - 财政年份:2024
- 资助金额:
$ 11.12万 - 项目类别:
Research Grant